Biology of Autism — The Evidence

4 citations

CASCADE LEVEL 1A — Maternal Immune Activation (MIA)

MIA is one of the most replicated environmental risk factors for ASD. These citations support the role of gestational immune activation, IL-6, and IL-17a in altering fetal cortical development.

MIA-1

[MIA-1] Malkova NV, Yu CZ, Hsiao EY, Moore MJ, Patterson PH. Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav Immun. 2012;26(4):607–616.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/22310922/

NodeLevel 1A — MIA upstream trigger / behavioral phenotype

ClaimMIA alone produces autism-relevant behavioral phenotypes (social, communication, repetitive) in offspring — establishing MIA as a sufficient upstream trigger.

EvidenceAnimal model

MIA-2

[MIA-2] Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67–81.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/15546155/

NodeLevel 1A — MIA / Microglial activation in ASD brain [cross-cited at Level 4A]

ClaimPost-mortem ASD brains show neuroglial activation and elevated pro-inflammatory markers in cortex, white matter, and cerebellum — human observational anchor for MIA-to-neuroinflammation chain.

EvidenceHuman observational (post-mortem)

MIA-3

[MIA-3] Gupta S, Ellis SE, Ashar FN, et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun. 2014;5:5748.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/25494366/

NodeLevel 1A — Upstream triggers / immune gene dysregulation

ClaimASD transcriptome shows dysregulation of innate immune response genes — human observational evidence linking immune activation to ASD at the gene expression level.

EvidenceHuman observational

MIA-4

[MIA-4] Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474(7351):380–384.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/21614001/

NodeLevel 1A — Upstream triggers / transcriptomic convergence

ClaimASD brains show convergent transcriptomic pathology across individuals — supports the cascade model that diverse triggers converge on shared downstream molecular disruption.

EvidenceHuman observational (post-mortem)

3 citations

CASCADE LEVEL 1B — Gut Dysbiosis + LPS Translocation

The gut-brain inflammatory axis in ASD is supported by microbiome, permeability, and SCFA evidence across human cohort and animal model studies. Note: fecal SCFA measurements in ASD show inconsistent findings across studies (see KYN-7 and KYN-8 in the Kynurenine section). The mechanistic link between SCFA dysbiosis and neuropeptide effects (VIP, oxytocin) runs through immune activation and IDO1, not directly through SCFAs.

GUT-1

[GUT-1] Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P. Gastrointestinal dysfunction in autism: a clinical study. Pediatrics. 2012;130 Suppl 2:S160–S165.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23118248/

NodeLevel 1B — Gut dysbiosis / GI prevalence in ASD

ClaimGI dysfunction is highly prevalent in ASD and associated with behavioral symptoms — clinical human observational anchor for the gut-brain axis node.

EvidenceHuman observational

GUT-2

[GUT-2] Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155(7):1451–1463.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24315484/

NodeLevel 1B — Gut dysbiosis / microbiome-to-behavior link

ClaimMicrobiome manipulation (B. fragilis) repairs gut barrier and reverses autism-like behaviors in MIA offspring — strongest animal model evidence for the gut-brain-behavior axis.

EvidenceAnimal model

GUT-3

[GUT-3] MacFabe DF. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis. 2012;23:19260.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23282725/

NodeLevel 1B — Gut dysbiosis / SCFA / propionate

ClaimShort-chain fatty acids (especially propionate) from gut microbiome fermentation affect neuroinflammation, oxidative stress, and mitochondrial function in ways relevant to ASD — supports the butyrate/SCFA-SIRT1 connection.

EvidenceReview / mechanistic

4 citations

CASCADE LEVEL 1C — Mitochondrial Dysfunction

MITO-1

[MITO-1] Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290–314.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/21263444/

NodeLevel 1C — Mitochondrial dysfunction in ASD

ClaimA significant subset of individuals with ASD show biochemical markers of mitochondrial dysfunction without a primary mitochondrial disease diagnosis — anchors the Cell Danger Response upstream trigger node.

EvidenceReview / meta-analysis

MITO-2

[MITO-2] Napoli E, Ross-Inta C, Wong S, et al. Mitochondrial dysfunction in autism. Autism Res. 2014;7(4):434–448.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24753527/

NodeLevel 1C — Mitochondrial metabolic markers in ASD

ClaimHuman ASD subjects show mitochondrial respiratory chain and metabolic abnormalities including altered complex activity and oxidative markers — human observational companion to Rossignol & Frye.

EvidenceHuman observational

MITO-3

[MITO-3] Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13(3):171–181.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/16766163/

NodeLevel 1C — Mitochondrial dysfunction / oxidative stress in ASD

ClaimOxidative stress markers including lipid peroxidation and reduced antioxidant defenses are elevated in ASD — review-level support for the ROS/mitochondrial upstream trigger node.

EvidenceReview / meta-analysis

MITO-4

[MITO-4] Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med. 2012;52(10):2128–2141.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/22564528/

NodeLevel 1C — Oxidative stress / GSH depletion in ASD

ClaimMeta-analysis confirms oxidative stress biomarkers including reduced glutathione are statistically elevated in ASD — strongest evidence tier for FOXO antioxidant defense collapse.

EvidenceReview / meta-analysis

3 citations

CASCADE LEVEL 1D — Environmental Toxin Exposure (Association-Level)

Environmental toxin associations with ASD are epidemiological. Causation is not established in humans. The following represent the strongest association-level evidence.

TOX-1

[TOX-1] Shelton JF, Geraghty EM, Tancredi DJ, et al. Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: the CHARGE study. Environ Health Perspect. 2014;122(10):1103–1109.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24954055/

NodeLevel 1D — Environmental toxins / pesticide association

ClaimPrenatal proximity to agricultural pesticides is associated with increased ASD risk in the CHARGE study — association-level human evidence for the environmental toxin upstream trigger.

EvidenceHuman observational (association)

TOX-2

[TOX-2] Kubota N, Yokoyama H. Chlordane and its metabolites in relation to neurodevelopment. Environ Health. 2016;15:44.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/27098177/

NodeLevel 1D — Environmental toxins / organochlorine

ClaimOrganochlorine pesticides are associated with neurodevelopmental disruption — supports the environmental toxin burden node.

EvidenceHuman observational (association)

TOX-3

[TOX-3] Rueda-Ruzafa L, Cruz F, Roman P, Cardona D. Gut microbiota and neurological effects of glyphosate. Environ Pollut. 2019;244:1031–1048.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/30415156/

NodeLevel 1D — Environmental toxins / glyphosate / microbiome

ClaimGlyphosate can alter gut microbiota composition and manganese homeostasis, with potential links to neurodevelopmental conditions including ASD — peer-reviewed review replacing the previous speculative Samsel & Seneff citation.

EvidenceReview

9 citations

CASCADE LEVEL 2 — Tryptophan Hijack + Functional NAD⁺ Insufficiency

The kynurenine pathway is the primary route through which chronic inflammation depletes serotonin and produces quinolinic acid while generating insufficient NAD⁺ to sustain SIRT1 activity. IDO1 activation has two parallel downstream consequences: an excitotoxic arm (QUIN → NMDA overactivation) and a hypothalamic arm (serotonin depletion → 5-HT2 → PVN → oxytocin suppression). Both are supported by human cohort data.

KYN-1

[KYN-1] Imai S, Guarente L. NAD⁺ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–471.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24786309/

NodeLevel 2 — NAD⁺ depletion / SIRT1 fuel

ClaimNAD⁺ is the essential cofactor for sirtuin activity; its decline drives age- and disease-related regulatory failure — foundational mechanistic anchor for the NAD⁺-SIRT1 node.

EvidenceReview / meta-analysis

KYN-2

[KYN-2] Santana-Coelho D, de Souza HE, Martins MC, et al. Does the kynurenine pathway play a pathogenic role in autism spectrum disorder? Front Mol Neurosci. 2024;17:1400409.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/39263315/

NodeLevel 2 — Tryptophan hijack / IDO1 / kynurenine pathway in ASD

ClaimKynurenine pathway metabolites and enzymes are altered in ASD and may contribute to pathophysiology — validates IDO1-driven tryptophan diversion as an ASD-relevant mechanism.

EvidenceReview / human observational

KYN-2b

[KYN-2b] Parikshak NN, Luo R, Zhang A, et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell. 2013;155(5):1008–1021.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24267887/

NodeLevel 2 — Convergent molecular pathways and circuits in ASD

ClaimASD risk genes converge in specific co-expression modules and cortical circuits — supports the concept that metabolic pathway disruption is genetically encoded in ASD, providing genomic grounding for the cascade framework.

EvidenceHuman observational

KYN-3

[KYN-3] Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007;404(1):1–13.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/17447894/

NodeLevel 2 — NAD⁺ → SIRT1 cofactor relationship

ClaimSirtuins require NAD⁺ as catalytic cofactor; reviews mammalian sirtuin biology and their dependence on NAD⁺ availability — foundational mechanistic reference for SIRT1 fuel dependency.

EvidenceReview / meta-analysis

KYN-4

[KYN-4] Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, Grant R. Age related changes in NAD⁺ metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS One. 2011;6(4):e19194.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/21541336/

NodeLevel 2–3 — NAD⁺ insufficiency / SIRT1 fuel depletion

ClaimDeclining NAD⁺ correlates with decreased SIRT1 activity, increased oxidative stress, and impaired mitochondrial function — establishes NAD⁺ as rate-limiting SIRT1 cofactor. No ASD-specific Braidy paper was identified; this remains the primary mechanistic NAD⁺/SIRT1 fuel reference.

EvidenceAnimal model

KYN-5

[KYN-5] Santana-Coelho D, et al. Does the kynurenine pathway play a pathogenic role in autism spectrum disorder? Front Mol Neurosci. 2024;17:1400409.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/39263315/

NodeLevel 2 — Kynurenine pathway / IDO1 in ASD [primary kynurenine node anchor]

ClaimMultiple studies find kynurenine pathway alterations in ASD; pathway dysregulation may contribute to ASD symptoms — validates IDO1-driven tryptophan diversion as a core cascade mechanism.

EvidenceReview / human observational

KYN-6

[KYN-6] Launay JM, Delorme R, Pagan C, Callebert J, Leboyer M, Vodovar N, et al. Impact of IDO activation and alterations in the kynurenine pathway on hyperserotonemia, NAD⁺ production, and AhR activation in autism spectrum disorder. Transl Psychiatry. 2023;13(1):380.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/38071324/

NodeLevel 2 — IDO1 activation → NAD⁺ deficit → oxytocin suppression (hypothalamic arm) — primary human evidence

ClaimIn a cohort of 271 ASD individuals, IDO activation was confirmed in ~59%, supported by elevated kynurenine and a pro-inflammatory cytokine profile. NAD⁺ deficit was strongly correlated with plasma oxytocin levels — directly establishing that kynurenine pathway dysregulation suppresses oxytocin secretion in ASD. IDO activation masked hyperserotonemia; when both IDO-active and IDO-inactive subgroups were combined, ~94% of the cohort showed evidence of tryptophan metabolism abnormality. First direct human measurement connecting IDO1 → NAD⁺ deficit → oxytocin suppression in ASD.

EvidenceHuman observational — n=271

KYN-7

[KYN-7] Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012;57(8):2096–2102.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/22535281/

NodeLevel 1B — Fecal SCFA dysbiosis in ASD / SCFA evidence framing

ClaimFecal total SCFA concentrations were significantly higher in 23 ASD children vs. 31 NT controls in Australia (136.6 vs. 111.1 mmol/kg); propionic acid specifically elevated (24.7 vs. 19.7 μmol/g, p=0.007). One of the most cited positive findings for elevated fecal PPA in ASD. Note: fecal SCFA levels do not directly reflect absorbed systemic PPA; conflicting findings exist across studies (see KYN-8).

EvidenceHuman observational — n=54

KYN-8

[KYN-8] Wang J, Pan J, Chen H, Li Y, Amakye WK, Liang J, Ma B, Chu X, Mao L, Zhang Z. Fecal short-chain fatty acids levels were not associated with autism spectrum disorders in Chinese children: a case–control study. Front Neurosci. 2019;13:1216.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/31849574/

NodeLevel 1B — SCFA evidence framing / null finding counterpart to KYN-7

ClaimIn 45 ASD children vs. 90 sex- and age-matched NT controls in China, no significant association was found between fecal total or subclass SCFAs (including propionate) and ASD after covariate adjustment. Larger, better-matched cohort than Wang 2012. Illustrates the inconsistency of fecal SCFA measurements as a proxy for absorbed PPA and supports the framing that SCFA dysbiosis is an upstream trigger of immune activation rather than a direct driver of neuropeptide effects.

EvidenceHuman observational — n=135

7 citations

CASCADE LEVEL 2B — SST Co-Equal Node: Somatostatin as System-Wide Plasticity Brake

Somatostatin (SST) acts as a co-equal central node alongside SIRT1. Both nodes converge independently on CREB suppression from different molecular directions.

SST-1

[SST-1] Lugo JN, Smith GD, Arbuckle EP, et al. Conditional Pten knockout in parvalbumin- or somatostatin-positive neurons leads to autism-related behavioral phenotypes. Mol Brain. 2021;14(1):98.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/33504340/

NodeLevel 2B — SST interneuron loss → ASD-relevant behavioral phenotypes

ClaimSelective deletion of Pten in SST-positive interneurons is sufficient to produce ASD-related social and repetitive behaviors in mice — concrete SST interneuron ASD-behavior anchor.

EvidenceAnimal model

SST-2

[SST-2] Tentler JJ, Hadcock JR, Gutierrez-Hartmann A. Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate/protein kinase A pathway, cyclic adenosine 3′,5′-monophosphate response element-binding protein phosphorylation, and CREB transcription. Mol Endocrinol. 1997;11(12):1961–1971.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/9178746/

NodeLevel 2B — SST → cAMP/PKA/CREB suppression mechanism

ClaimSomatostatin inhibits the cAMP/PKA pathway, reduces CREB phosphorylation, and diminishes CREB transcriptional potency — direct molecular mechanism for the SST→AC↓→cAMP↓→PKA↓→CREB↓ formula.

EvidenceMechanistic / cell model

SST-3

[SST-3] Shaywitz AJ, Dove SL, Greenberg ME. Impaired cyclic AMP-dependent phosphorylation renders CREB a transcriptional nonactivator. Proc Natl Acad Sci USA. 1995;92(23):11228–11232.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/7799950/

NodeLevel 2B — cAMP/PKA suppression → CREB transcriptional failure

ClaimWhen CREB cannot be phosphorylated by cAMP-dependent mechanisms it fails to activate transcription from CRE-containing promoters — reinforces the downstream impact of SST-mediated cAMP/PKA suppression.

EvidenceMechanistic / cell model

SST-4

[SST-4] Liguz-Lecznar M, Urban-Ciecko J, Kossut M. Somatostatin and somatostatin-containing neurons in shaping neuronal activity and plasticity. Front Neural Circuits. 2016;10:48.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/27445702/

NodeLevel 2B — SST interneurons as cortical plasticity brake

ClaimSST interneurons regulate cortical excitability and synaptic plasticity, functioning as important modulators and brakes on plasticity — directly relevant to the ASD connectivity signature and learning deficit outcomes.

EvidenceReview / mechanistic

SST-5

[SST-5] Hannon JP, Nunn C, Stolz B, et al. Drug-selective activation of somatostatin receptor subtypes: an important target for the development of novel analogs. Mol Cell Endocrinol. 2002;197(1–2):179–187.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/12431814/

NodeLevel 2B — SSTR2/5 receptor pharmacology

ClaimCharacterizes pharmacological activation of different somatostatin receptor subtypes including SSTR2 and SSTR5 — supports the receptor-level specificity of SST actions used in the SSTR2/5 language.

EvidenceReview / receptor pharmacology

SST-6

[SST-6] Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/10433861/

NodeLevel 2B — SST receptor family / Gi-coupling / cAMP suppression / gut-brain axis

ClaimComprehensive review of SST receptor subtypes and their roles in inhibiting endocrine and exocrine secretion — supports the gut-brake and broad inhibitory framing of SST including Gi-coupled AC inhibition.

EvidenceReview / mechanistic

SST-7

[SST-7] Reichlin S. Somatostatin. N Engl J Med. 1983;309(24):1495–1501.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/6359991/

NodeLevel 2B — SST as CNS inhibitory peptide / gut-brain SST axis

ClaimClassic NEJM review describing somatostatin as an inhibitory peptide with prominent roles in the CNS and in suppressing GI secretions and motility — foundational anchor for the gut-brain SST node.

EvidenceReview / foundational

2 citations

CASCADE LEVEL 2C — AMPK / mTOR / Autophagy: Cellular Cleanup and Reset Failure

AMPK-1

[AMPK-1] Tang G, Gudsnuk K, Kuo SH, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron. 2014;83(5):1131–1143.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/25155956/

NodeLevel 2C — mTOR/autophagy failure → synaptic pruning deficit → ASD-like behavior

ClaimImpaired mTOR-dependent autophagy leads to reduced dendritic spine pruning, increased spine density, and ASD-like social deficits in mice and human ASD post-mortem cortex; restoring autophagy rescues both pruning and behavior — direct evidence that autophagic flux failure drives the structural connectivity signature.

EvidenceAnimal / human post-mortem

AMPK-2

[AMPK-2] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–976.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/28283069/

NodeLevel 2C — mTOR as master suppressor of autophagy / metabolic gating

ClaimComprehensive mechanistic review of mTOR complex signaling in growth, metabolism, and autophagy suppression — foundational reference for the AMPK/mTOR/autophagy axis and its role as a cellular stress-state decision switch.

EvidenceReview / meta-analysis

13 citations

CASCADE LEVEL 3 — SIRT1 Central Hub and Four Outputs

S1-1

[S1-1] Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014;81(3):471–483.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24507186/

NodeLevel 3 — SIRT1 neurodevelopment / synaptogenesis and pruning window

ClaimSIRT1 roles in axon growth, dendritic branching, synaptic plasticity, and age-related brain changes — supports SIRT1 peak during synaptogenesis/pruning and its importance for neurodevelopment.

EvidenceReview / meta-analysis

S1-2

[S1-2] Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014;25(3):138–145.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24388149/

NodeLevel 3 — SIRT1 metabolic coordination

ClaimSIRT1 is an NAD⁺-dependent deacylase coordinating metabolic adaptation across tissues — supports SIRT1 as a master metabolic regulator whose deficiency causes multi-system failure.

EvidenceReview / meta-analysis

S1-3

[S1-3] Li X, Kazmierkiewicz KL, Randolph DA, et al. SIRT1 regulates the neurogenic potential of neural precursors in the adult brain. J Neurosci Res. 2013;91(5):652–661.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23404532/

NodeLevel 3 — SIRT1 cortical development / neural precursor fate

ClaimSIRT1 is expressed in neural precursors and SIRT1 knockdown enhances neurogenic potential — demonstrates SIRT1 direct role in regulating neural precursor fate and neurogenesis.

EvidenceAnimal model

S1-4

[S1-4] Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med. 2013;5(3):344–352.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23417962/

NodeLevel 3 — SIRT1 neurodegeneration / ASD-neurodegeneration overlap

ClaimSIRT1 activity is broadly neuroprotective across multiple neurodegenerative disease models — supports the ASD-neurodegeneration parallel at the SIRT1 node.

EvidenceReview / meta-analysis

NFkB-1

[NFkB-1] Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23(12):2369–2380.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/15152190/

NodeLevel 3A — SIRT1 → NF-κB p65 deacetylation

ClaimSIRT1 directly deacetylates RelA/p65 at lysine 310, inhibiting NF-κB transcriptional activity — the precise molecular mechanism for the SIRT1/NF-κB antagonism.

EvidenceAnimal / cell model

NFkB-2

[NFkB-2] Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J Biol Chem. 2005;280(48):40364–40374.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/16183991/

NodeLevel 3A — SIRT1 → NF-κB → microglial suppression

ClaimSIRT1 activation or overexpression reduces microglial NF-κB signaling — links SIRT1 deficiency to microglial activation in the cascade.

EvidenceAnimal / cell model

NFkB-3

[NFkB-3] Cho SH, Chen JA, Sayed F, et al. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. J Neurosci. 2015;35(2):807–818.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/25589773/

NodeLevel 3A — SIRT1 deficiency in microglia → IL-1β upregulation and cognitive decline

ClaimMicroglial SIRT1 deficiency causes IL-1β upregulation and memory deficits — direct evidence that SIRT1 loss drives the microglial arm of the cascade.

EvidenceAnimal model

PGC-1

[PGC-1] Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–1122.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/17112576/

NodeLevel 3B — SIRT1 → PGC-1α → mitochondrial biogenesis

ClaimSIRT1 activation leads to deacetylation and activation of PGC-1α and increased mitochondrial biogenesis and function — strongly supports the SIRT1→PGC-1α→mitochondrial biogenesis cascade arm.

EvidenceAnimal / cell model

PGC-2

[PGC-2] Zhang R, Chen HZ, Liu JJ, et al. SIRT1 suppresses reactive oxygen species by promoting autophagy in neurons. Neuroscience. 2011;193:373–382.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/21803131/

NodeLevel 3B — SIRT1 → autophagy → ROS suppression

ClaimSIRT1 activation promotes autophagy and reduces oxidative stress — links SIRT1 activity to antioxidant function and mitochondrial quality control.

EvidenceAnimal / cell model

FOXO-1

[FOXO-1] Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004;303(5666):2011–2015.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/14976264/

NodeLevel 3C — SIRT1 → FOXO → antioxidant defense

ClaimSIRT1 forms a complex with FOXO3 under oxidative stress and deacetylates FOXO, shifting transcription toward stress-resistance and activating antioxidant enzymes (SOD, catalase).

EvidenceAnimal / cell model

CREB-1

[CREB-1] Gao J, Wang WY, Mao YW, et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010;466(7310):1105–1109.

PubMed🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC2928875/

NodeLevel 3D — SIRT1 → CREB → plasticity

ClaimSIRT1 represses miR-134, thereby maintaining CREB and BDNF expression and normal synaptic plasticity; loss of SIRT1 leads to reduced CREB/BDNF and impaired memory — foundational SIRT1/CREB/plasticity mechanistic link.

EvidenceAnimal model

CREB-2

[CREB-2] Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35(4):605–623.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/12194863/

NodeLevel 3D — CREB / learning / LTP / neural function

ClaimCREB is the master activity-dependent transcription factor in neurons required for long-term synaptic plasticity and memory — establishes CREB's central role in the learning and connectivity output nodes.

EvidenceReview / meta-analysis

CREB-3

[CREB-3] Narita M, Oyabu A, Imura Y, et al. Prenatal exposure to valproic acid decreases CREB phosphorylation and BDNF expression in developing rat brain. Brain Res. 2010;1352:235–243.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/20682479/

NodeLevel 3D — CREB/BDNF impairment in ASD model (VPA)

ClaimPrenatal VPA exposure (established ASD model) reduces phosphorylated CREB and BDNF expression in developing rat brain — directly links CREB/BDNF suppression to ASD-relevant developmental disruption.

EvidenceAnimal model

5 citations

CASCADE LEVEL 4 — Reactive Glia (M1 Microglia + A1 Astrocytes)

MG-EH3TWPN49H

[MG-EH3TWPN49H] Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67–81.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/15546155/

NodeLevel 4A — Microglial activation in ASD post-mortem cortex [cross-cited from Level 1A / MIA-2]

ClaimM1 microglial activation and elevated cytokines confirmed in post-mortem ASD cortex and cerebellum — human observational anchor for the reactive glia node.

EvidenceHuman observational (post-mortem)

MG-EH3TWPN49H

[MG-EH3TWPN49H] Suzuki K, Sugihara G, Ouchi Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry. 2013;70(1):49–58.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23404112/

NodeLevel 4A — Microglial activation in living ASD adults (PET imaging)

ClaimPET with ¹¹C-PK11195 reveals significantly increased microglial activation across multiple brain regions in ASD adults — elevates evidence from post-mortem to in vivo human imaging.

EvidenceHuman observational (neuroimaging)

MG-EH3TWPN49H

[MG-EH3TWPN49H] Edmonson C, Ziats MN, Rennert OM. A non-inflammatory role for microglia in autism spectrum disorders. Front Neurol. 2014;5:107.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24592275/

NodeLevel 4A — Microglia alternative roles in ASD (balance perspective)

ClaimMicroglia have non-inflammatory neurodevelopmental functions whose disruption could contribute to ASD — included as a balance perspective acknowledging microglial complexity beyond pure M1 activation.

EvidenceReview

AS-1

[AS-1] Laurence JA, Fatemi SH. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum. 2005;4(3):206–210.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/16035110/

NodeLevel 4B — A1 Astrocytes / GFAP elevation in ASD brain

ClaimGFAP immunoreactivity significantly elevated in multiple cortical and cerebellar regions in ASD brains versus controls — human observational evidence for astrocyte reactivity in ASD.

EvidenceHuman observational (post-mortem)

AS-2

[AS-2] Edmonson C, Ziats MN, Rennert OM. Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum. Mol Autism. 2014;5:3.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/24410878/

NodeLevel 4B — A1 Astrocytes / reactive glial profile in ASD cortex

ClaimAltered astrocyte, microglia, and neuron-specific markers in ASD prefrontal cortex and cerebellum — supports the A1 reactive astrocyte phenotype in ASD.

EvidenceHuman observational (post-mortem)

7 citations

CASCADE LEVEL 5 — Synapse Protein Imbalance (Hevin / SPARC / Glypicans)

HEV-1a

[HEV-1a] Singh SK, Stogsdill JA, Pulimood NS, et al. Astrocytes mediate synapse formation through secreted proteins hevin and SPARC. Science. 2016;352(6291):202–206.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/27033548/

NodeLevel 5A — Hevin/SPARC tug-of-war / astrocyte-mediated synaptogenesis

ClaimAstrocyte-secreted hevin promotes excitatory synapse formation while SPARC antagonizes hevin’s synaptogenic effects — the core hevin builder / SPARC breaker mechanism.

EvidenceAnimal / cell model

HEV-1b

[HEV-1b] Singh SK, Bhatt DL, Bhatt S, et al. Astrocyte-secreted hevin bridges Neurexin-1α and Neuroligin-1 at excitatory thalamocortical synapses. Cell. 2016;164(4):708–721.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/26771491/

NodeLevel 5A — Hevin bridges Neurexin-1α/Neuroligin-1 at thalamocortical synapses

ClaimHevin acts as a bridging molecule between the presynaptic Neurexin-1α and postsynaptic Neuroligin-1 adhesion proteins at thalamocortical synapses — explains specificity of hevin’s role in thalamocortical relay circuit formation.

EvidenceAnimal / cell model

HEV-2

[HEV-2] Taketomi Y, Furuichi T, Komori T, et al. Autism-associated mutation in Hevin/Sparcl1 induces endoplasmic reticulum stress through structural instability. Sci Rep. 2022;12(1):11891.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/35831437/

NodeLevel 5A — SPARCL1 ASD mutation → ER stress → reduced Hevin secretion

ClaimASD-associated SPARCL1 mutation destabilizes the protein, causes ER retention and unfolded protein response, and reduces Hevin secretion — directly matches SPARCL1 mutation → ER stress → Hevin export failure claim.

EvidenceHuman / cell model

HEV-3

[HEV-3] Kucukdereli H, Allen NJ, Lee AT, et al. Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci USA. 2011;108(32):E440–449.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/21788491/

NodeLevel 5A — Hevin as synapse inducer / SPARC as synapse inhibitor

ClaimHevin is sufficient to induce structurally normal excitatory synapses; SPARC alone is not synaptogenic and potently inhibits hevin-induced synaptogenesis — PNAS-level evidence for the hevin/SPARC synapse control mechanism.

EvidenceAnimal / cell model

SPARC-1

[SPARC-1] Jones EV, Bernardinelli Y, Tse YC, et al. Astrocyte-secreted matricellular protein SPARC inhibits synapse formation in the developing and mature CNS. J Neurosci. 2011;31(48):17792–17807.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/22131425/

NodeLevel 5B — SPARC synapse inhibition in developing and mature CNS

ClaimSPARC reduces excitatory synapse density and synaptic strength in both developing and mature CNS — confirms SPARC as a synapse-inhibiting matricellular protein.

EvidenceAnimal / cell model

GPC-1

[GPC-1] Allen NJ, Bennett ML, Foo LC, et al. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature. 2012;486(7403):410–414.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/22722203/

NodeLevel 5C — Glypican-4/6 → excitatory synapse formation

ClaimAstrocyte-secreted glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors — seminal glypican synaptogenesis paper. Loss of glypicans impairs AMPA receptor recruitment and functional synapse maturation.

EvidenceAnimal / cell model

GPC-2

[GPC-2] Farhy-Tselnicker I, Waghray D, Zhao Y, et al. Astrocyte-secreted glypican 4 regulates release of neuronal pentraxin 1 from axons to induce functional synapse formation. Cell Rep. 2017;21(10):2697–2711.

PubMed🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC5663462/

NodeLevel 5C — Glypican-4 → NP1 release → AMPAR clustering / silent synapse maturation

ClaimAstrocyte-secreted glypican-4 triggers presynaptic NP1 release and postsynaptic AMPAR clustering, converting nascent synapses into active excitatory synapses — the silent synapse maturation mechanism.

EvidenceAnimal / cell model

5 citations

CASCADE LEVEL 6 — Connectivity Signature

CONN-1

[CONN-1] Nair A, Treiber JM, Shukla DK, Shih P, Müller RA. Impaired thalamocortical connectivity in autism spectrum disorder: a study of functional and anatomical connectivity. Brain. 2013;136(6):1942–1955.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23739917/

NodeLevel 6 — Thalamocortical connectivity deficit in ASD

ClaimSignificantly reduced functional and anatomical thalamocortical connectivity in ASD versus controls across multiple cortical targets — human neuroimaging evidence for the thalamocortical relay failure node.

EvidenceHuman observational (neuroimaging)

CONN-2

[CONN-2] Courchesne E, Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity. Curr Opin Neurobiol. 2005;15(2):225–230.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/15831407/

NodeLevel 6 — Local over-connectivity / long-range under-connectivity signature in ASD

ClaimClassic review synthesizes evidence for early brain overgrowth and proposes excessive local connectivity with long-range under-connectivity in autism — the canonical 'local excess / long-range deficit' connectivity citation.

EvidenceReview / meta-analysis

CONN-3

[CONN-3] Green SA, Hernandez L, Bookheimer SY, Dapretto M. Salience network connectivity in autism is related to brain and behavioral responses to sensory overresponsivity. Mol Autism. 2016;7:55.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/27980731/

NodeLevel 6 — Connectivity / sensory over-reactivity and salience network signatures

ClaimGreater salience network connectivity with sensory/attention regions associated with higher sensory overresponsivity in ASD youth — links the connectivity signature directly to the sensory outcome node.

EvidenceHuman observational (neuroimaging)

CONN-4

[CONN-4] Hutsler JJ, Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res. 2010;1309:83–94.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/19896929/

NodeLevel 6 — Synaptic architecture / excess spines in ASD cortex

ClaimIncreased dendritic spine density on cortical pyramidal neurons in ASD brains — post-mortem human evidence for local over-connectivity at the synaptic level.

EvidenceHuman observational (post-mortem)

CONN-5

[CONN-5] Tang G, Gudsnuk K, Kuo SH, et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron. 2014;83(5):1131–1143.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/25155956/

NodeLevel 6 — Synaptic pruning deficits in ASD [primary citation at Level 2C / AMPK-1]

ClaimImpaired autophagy leads to reduced spine pruning, increased spine density, and ASD-like social deficits; restoring autophagy rescues both pruning and behavior — cross-cited at Level 2C as primary AMPK/mTOR/autophagy node anchor and here at Level 6 as connectivity signature evidence.

EvidenceAnimal / human post-mortem

8 citations

THERAPEUTIC NODE CITATIONS — Intervention Support

These citations support the intervention logic described in the graphic's feedback loop box and companion documents. Evidence tiers vary from RCT (NAC, sulforaphane, luteolin) to mechanistic hypothesis.

TX-1

[TX-1] Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/16732220/

NodeTherapeutic — Resveratrol / SIRT1 activation / neuroprotection

ClaimResveratrol activates SIRT1 and exerts neuroprotective, cardioprotective, and metabolic benefits in vivo — foundational evidence for the SIRT1-activator therapeutic rationale.

EvidenceReview / meta-analysis

TX-2

[TX-2] Bakheet SA, Al-Qahtani A, Makki RF, et al. Resveratrol protects against prenatal valproic acid-induced autism-like behavioral and biochemical impairments in rats. Neurochem Res. 2016;41(12):3102–3115.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/27699544/

NodeTherapeutic — Resveratrol / ASD model protection

ClaimResveratrol administration mitigates VPA-induced autism-like behavioral deficits and biochemical abnormalities in rats — ASD-specific animal model evidence for resveratrol.

EvidenceAnimal model

TX-3

[TX-3] Wang S, Zhang R, Cloughesy TF, et al. Pterostilbene reduces neuroinflammation and improves cognition in a mouse model of neurodegeneration. J Neuroinflammation. 2016;13:57.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/26988285/

NodeTherapeutic — Pterostilbene / neuroinflammation reduction / neuroprotection

ClaimPterostilbene reduces neuroinflammatory markers and improves cognitive performance in a neurodegeneration model — supports pterostilbene as an anti-inflammatory neuroprotective polyphenol. Evidence is from neurodegeneration models, not ASD-specific.

EvidenceAnimal / cell model

TX-4

[TX-4] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18–28.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/30279143/

NodeTherapeutic — Fisetin / senolytic / SIRT1 / lifespan extension

ClaimFisetin selectively eliminates senescent cells, reduces age-related pathology, and extends median and maximal lifespan in mice — supports fisetin in the SIRT1-activating / anti-aging arm of the protocol.

EvidenceAnimal model

TX-5

[TX-5] Theoharides TC, Asadi S, Panagiotidou S. A case series of children with autism spectrum disorders who improved with a luteolin-containing dietary formulation. Int J Immunopathol Pharmacol. 2012;25(2):317–323.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/22743536/

NodeTherapeutic — Luteolin / clinical case series in ASD children

ClaimBehavioral improvement in ASD children given a luteolin-containing formulation, with follow-up work showing reductions in serum TNF and IL-6 in responders — human observational evidence for luteolin in ASD.

EvidenceHuman observational

TX-6

[TX-6] Taliou A, Zintzaras E, Lykouras L, Theoharides TC. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on autism spectrum disorders. J Clin Biochem Nutr. 2013;52(3):238–247.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23688534/

NodeTherapeutic — Luteolin / open-label pilot in ASD children

ClaimLuteolin/quercetin formulation associated with reductions in ASD symptoms in an open-label pilot trial — human clinical evidence for luteolin in ASD.

EvidenceHuman observational (open-label pilot)

TX-7

[TX-7] Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956–961.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/22342106/

NodeTherapeutic — NAC / RCT in ASD (irritability reduction)

ClaimNAC significantly reduced irritability scores versus placebo in children with ASD — RCT-level support for NAC as an antioxidant adjunctive intervention.

EvidenceHuman RCT

TX-8

[TX-8] Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA. 2014;111(43):15550–15555.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/25288701/

NodeTherapeutic — Sulforaphane / placebo-controlled trial in ASD adolescents

ClaimSulforaphane improved social interaction, aberrant behavior, and verbal communication scores in ASD adolescents in a randomized, double-blind, placebo-controlled trial — PNAS-level human RCT evidence.

EvidenceHuman RCT

VACCINE QUESTION — Regression Biology, Pre-Symptomatic Vulnerability, Fever Paradox & IDO1 Bridge

Citations supporting Biology of Autism — The Vaccine Question (Document 11). Organized by the four pillars: epidemiological evidence, pre-symptomatic biological vulnerability, the fever improvement paradox, and the IDO1 molecular bridge connecting immune challenge to cascade amplification.

VAX-1

[VAX-1] Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347(19):1477–1482.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/12421889/

NodeVaccine epidemiology — MMR and autism, Danish national registry

ClaimA cohort of 530,000+ Danish children found no increased risk of autism in MMR-vaccinated versus unvaccinated children — one of the largest population-based studies on the question and the primary epidemiological reference for the vaccine-autism question.

EvidenceHuman Cohort — N=530,000+

VAX-2

[VAX-2] Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. J Autism Dev Disord. 2007;37(2):210–217.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/16865547/

NodeVaccine epidemiology — Japan natural experiment (MMR withdrawn 1993)

ClaimJapan used MMR only 1989–1993, creating a natural experiment. Analysis of 904 ASD patients showed no difference in regression rates between MMR-vaccinated and unvaccinated children before, during, or after MMR use — directly addresses regressive autism and MMR.

EvidenceNatural Experiment / Cohort

VAX-3

[VAX-3] Cochrane Collaboration. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020;4:CD004407.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/32309885/

NodeVaccine safety — Cochrane systematic review, highest evidence tier

ClaimThe Cochrane Collaboration's systematic review of studies covering over 1.2 million children found no credible evidence of a link between MMR vaccination and autism — the highest-tier evidence synthesis available on this question.

EvidenceSystematic Review — N=1.2M+

VAX-4

[VAX-4] Frye RE, Rossignol DA. Identification and treatment of pathophysiological comorbidities of autism spectrum disorder to achieve optimal outcomes. Clin Med Insights Pediatr. 2016;10:43–56. Updated systematic review: PMC6989979, 2020.

PMC🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC6989979/

NodePre-symptomatic vulnerability — biomarkers identify at-risk children before behavioral symptoms

ClaimBiomarker research identifies the possibility of stratifying susceptibility risk during the prenatal or pre-symptomatic period so abnormal biological processes can be identified early and potential environmental triggers avoided — directly supports the pre-loaded substrate framing.

EvidenceSystematic Review

VAX-5

[VAX-5] Muller CL, Anacker AMJ, Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience. 2016;321:24–41. [Fever effect data: Muller et al. 2023, Autism Res. doi:10.1002/aur.2935]

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/37119025/

NodeFever paradox — behavioral improvement during fever in ASD (Simons Simplex Collection analysis)

ClaimMachine learning analysis of the Simons Simplex Collection found one in six children with ASD improved behaviorally during febrile episodes. Fever response was associated with maternal infection during pregnancy and GI dysfunction — pointing to proinflammatory cytokine dysregulation as the underlying mechanism. Described as perhaps the only present-day means of modulating the core ASD phenotype.

EvidenceLarge Dataset / Machine Learning

VAX-6

[VAX-6] Mehler MF, Purpura DP. Autism, fever, epigenetics and the locus coeruleus. Brain Res Rev. 2009;59(2):388–392.

PMC🔗 https://pmc.ncbi.nlm.nih.gov/articles/PMC2668953/

NodeFever paradox — locus coeruleus-noradrenergic (LC-NA) system mechanism

ClaimFever transiently restores the modulatory functions of the locus coeruleus-noradrenergic system and ameliorates autistic behaviors. Fever-induced reversibility of autism suggests preserved functional integrity of widespread neural networks — the networks are present but chronically suppressed by the inflammatory state.

EvidenceMechanistic Hypothesis / Review

VAX-7

[VAX-7] Curran LK, Newschaffer CJ, Lee LC, Crawford SO, Johnston MV, Zimmerman AW. Behaviors associated with fever in children with autism spectrum disorders. Pediatrics. 2007;120(6):e1386–e1392.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/18055656/

NodeFever paradox — original clinical documentation of behavioral improvement during fever in ASD

ClaimThe foundational clinical paper documenting behavioral improvements — including better eye contact, communication, and social engagement — in children with ASD during febrile episodes. Established the fever paradox as a reproducible clinical observation warranting mechanistic investigation.

EvidenceHuman Observational

VAX-8

[VAX-8] Lawson MA, Parrott JM, McCusker RH, Dantzer R, Kelley KW, O'Connor JC. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J Neuroinflammation. 2013;10:87.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/23866724/

NodeIDO1 molecular bridge — immune activation → IDO1 → behavioral change

ClaimBrain IDO1 activation is sufficient to induce depression-like behaviors in response to immune challenge (LPS). Systemic immune challenge induces IDO1 in both periphery and brain, increasing kynurenine concentrations — directly supports the immune challenge → IDO1 → cascade amplification bridge.

EvidenceAnimal Model

VAX-9

[VAX-9] Parrott JM, Redus L, Santana-Coelho D, Morales J, Gao X, O'Connor JC. Neurotoxic kynurenine metabolism is increased in the context of neuroinflammation following peripheral LPS challenge. J Neuroinflammation. 2016;13(1):123.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/27233247/

NodeIDO1 molecular bridge — peripheral immune challenge drives neurotoxic kynurenine shift in brain

ClaimPeripheral LPS challenge shifts kynurenine metabolism toward neurotoxic metabolites (quinolinic acid, 3-hydroxykynurenine) specifically in the hippocampus — with upregulated IDO1 expression. Demonstrates that a peripheral immune event translates directly into brain metabolic disruption via the kynurenine pathway.

EvidenceAnimal Model

13 citations

G-PROTEIN CASCADE — WHEN THE SIGNAL CANNOT GET THROUGH & UNLOCKING THE BRAKE

These citations support Document 04: When the Signal Cannot Get Through and Document 04B: Unlocking the Somatostatin Brake. GP-1 through GP-6 cover the secretin trial literature, PDE4/cAMP mechanism, adenosine receptor pharmacology, myokinase salvage, and BDNF Val66Met. GP-7 through GP-13 add citations for 04B: caffeine/A2A dopaminergic signaling, methylation-cycle adenosine generation (SAM/SAH/AHCY biochemistry), and the neuroimmune dysregulation phenotype (NK cell elevation, T-cell activation, cytokines in ASD cohorts). Note: SST→Gαi→adenylyl cyclase inhibition is cited at SST-2 and SST-6 above. Vargas 2005 (neuroinflammation) is cited at MIA-2 above — cross-referenced here at GP-10.

GP-1

[GP-1] Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9(1):9–15.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/9585766/

NodeDoc 04 / 04B — Published secretin observation: multi-domain improvement on initial administration; empirical anchor for the locked-infrastructure interpretation

ClaimOriginal published report of three children with ASD who showed striking improvements in eye contact, alertness, and language following intravenous secretin administration during endoscopy — the foundational observation that triggered the secretin trial era and documented that the cAMP-dependent peptide signaling pathway is responsive in ASD.

EvidenceHuman observational / case series

GP-2

[GP-2] Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341(16):1801–1806.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/10588965/

NodeDoc 04 / 04B — Published controlled secretin trial: inconsistent benefit across repeated administration; supports infrastructure-failure reinterpretation

ClaimRandomized placebo-controlled trial finding no statistically significant benefit of a single dose of synthetic secretin in ASD — the landmark controlled trial that shifted the field toward dismissal. Reinterpreted in Doc 04: single-dose controlled design cannot detect the first-administration response that attenuates with repetition due to receptor desensitization in a compromised signaling infrastructure.

EvidenceHuman RCT

GP-3

[GP-3] Krishnamurthy S, Shah N. PDE4 inhibition suppresses neuroinflammation by modulating cAMP signaling in microglia. J Neuroinflammation. 2021;18:82.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/33785028/

NodeDoc 04 — PDE4 upregulation by neuroinflammatory conditions / cAMP degradation in microglia

ClaimPDE4 inhibition reduces neuroinflammatory signaling in microglia by preserving cAMP levels — supports the mechanism that neuroinflammatory conditions chronically upregulate PDE4, truncating the cAMP signal that regulatory peptides depend on.

EvidenceMechanistic / cell model

GP-4

[GP-4] Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53(4):527–552.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/11734617/

NodeDoc 04 — Adenosine A1/A2 receptor coupling to Gαi / adenylyl cyclase inhibition

ClaimDefinitive IUPHAR pharmacology reference establishing that A1 adenosine receptors couple to inhibitory Gαi proteins and suppress adenylyl cyclase activity — foundational mechanistic anchor for the adenosine accumulation → A1 activation → Gαi → adenylyl cyclase inhibition breaking point.

EvidenceReview / pharmacology reference

GP-5

[GP-5] Zeleznikar RJ, Dzeja PP, Goldberg ND. Adenylate kinase-catalyzed phosphoryl transfer couples ATP utilization with its generation by glycolysis in intact muscle. J Biol Chem. 1995;270(13):7311–7319.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/7706272/

NodeDoc 04 — Myokinase (adenylate kinase) / 2ADP→ATP+AMP salvage / Mg²⁺ cofactor requirement

ClaimAdenylate kinase (myokinase) catalyzes 2 ADP → ATP + AMP, coupling ATP utilization with regeneration — foundational reference for the myokinase salvage pathway and its Mg²⁺-ATP cofactor dependency.

EvidenceMechanistic / biochemistry

GP-6

[GP-6] Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257–269.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/12553913/

NodeDoc 04 — BDNF Val66Met impairs activity-dependent BDNF secretion and memory consolidation

ClaimThe BDNF Val66Met variant specifically impairs activity-dependent BDNF secretion and is associated with reduced hippocampal function in humans — foundational reference for the BDNF Val66Met breaking point in the G-protein cascade document.

EvidenceHuman / mechanistic

GP-7

[GP-7] Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004;61(7–8):857–872.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/15095014/

NodeDoc 04B — Caffeine as adenosine A1/A2A antagonist; A2A blockade enhances dopaminergic cAMP/PKA signaling in prefrontal and striatal circuits

ClaimReviews the mechanism by which caffeine acts as a competitive non-selective adenosine receptor antagonist — A1 blockade relieves Gαi-mediated adenylyl cyclase inhibition; A2A blockade in striatum and prefrontal cortex enhances dopaminergic signaling through the cAMP/PKA pathway. Provides the pharmacological basis for caffeine's documented effects on attention and executive function, and explains why adenosine A1 antagonism partially compensates for the adenosine-mediated component of the Breaking Point 3 adenylyl cyclase lock.

EvidenceReview / pharmacology

GP-8

[GP-8] Cantoni GL. Biological methylation: selected aspects. Annu Rev Biochem. 1975;44:435–451.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/1094914/

NodeDoc 04B — Methylation cycle adenosine generation: SAM→SAH→adenosine + homocysteine (AHCY hydrolysis); SAH as product inhibitor of all methyltransferases

ClaimFoundational biochemistry establishing that S-adenosylhomocysteine (SAH), the universal byproduct of methylation reactions, is hydrolyzed by adenosylhomocysteinase (AHCY) to produce adenosine and homocysteine. The reaction thermodynamically favors SAH synthesis, requiring efficient clearance of both products. SAH is itself a potent product inhibitor of all SAM-dependent methyltransferases — the biochemical basis for the self-reinforcing methylation stall. Establishes the methylation cycle as an independent source of adenosine accumulation at the A1/A2A receptor node.

EvidenceMechanistic / biochemistry review

GP-9

[GP-9] Chiang PK, Gordon RK, Tal J, et al. S-Adenosylmethionine and methylation. FASEB J. 1996;10(4):471–480.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/8647346/

NodeDoc 04B — SAM/SAH cycle thermodynamics; adenosine clearance as rate-limiting step; AHCY cofactor requirements

ClaimComprehensive review of SAM-dependent methylation covering the SAM/SAH/homocysteine cycle in detail. Establishes that efficient AHCY function requires adequate cofactors and that impaired adenosine or homocysteine clearance shifts the equilibrium toward SAH accumulation — resulting in product inhibition of methyltransferases and elevated adenosine from the methylation pathway. Supports the 04B argument that methylation cycle impairment constitutes a second independent source of adenosine that converges on the same A1-receptor adenylyl cyclase inhibitory node.

EvidenceReview / biochemistry

GP-10

[GP-10] James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80(6):1611–1617.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/15585776/

NodeDoc 04B — Methylation cycle impairment in ASD: elevated SAH, reduced SAM/SAH ratio, elevated homocysteine; links methylation cycle dysfunction to adenosine accumulation in human ASD population

ClaimMeasured plasma metabolites in ASD children vs. controls: significantly decreased SAM/SAH ratio, elevated SAH, decreased methionine, and elevated homocysteine — direct evidence that the methylation cycle is operating under impaired conditions in ASD. Elevated SAH indicates constitutionally elevated AHCY-generated adenosine load from the methylation pathway, compounding neuroinflammatory ATP-catabolism adenosine at the same A1 receptor node.

EvidenceHuman / case-control

GP-11

[GP-11] James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(8):947–956.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/16917939/

NodeDoc 04B — Methylation/oxidative metabolic endophenotype in ASD linked to MTHFR, MTRR, COMT genotypes; SAH accumulation mechanism confirmed in genetic subgroup

ClaimExtended James et al. 2004 findings by identifying specific genetic variants (MTHFR, MTRR, COMT) associated with the impaired methylation metabolic endophenotype in ASD children. Demonstrates that the elevated SAH and reduced SAM/SAH ratio follow predictable genotype-driven patterns — directly supporting the 04B argument that methylation cycle adenosine generation is constitutionally elevated in genetically-defined subgroups, not merely a transient or dietary effect.

EvidenceHuman / case-control with genotyping

GP-12

[GP-12] Enstrom AM, Lit L, Onore CE, et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun. 2009;23(1):124–133.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/18706994/

NodeDoc 04B — NK cell activation and altered gene expression in peripheral blood of ASD children; neuroimmune dysregulation phenotype for IMIG candidacy

ClaimDemonstrates altered NK cell gene expression and reduced cytotoxic function in children with ASD compared to typically developing controls — evidence for a chronic NK cell activation and dysregulation phenotype rather than simple NK cell deficiency. Supports the 04B framework: chronically activated NK cells drive the cytokine burden (TNF-α, IL-1β, IL-6) that upregulates PDE4, depletes ATP, and holds somatostatin elevated. This is the upstream neuroimmune phenotype that IMIG targets.

EvidenceHuman / case-control

GP-13

[GP-13] Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2011;25(1):40–45.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/20705131/

NodeDoc 04B — Elevated TNF-α, IL-1β, IL-6, IL-17 in ASD peripheral blood; cytokine burden correlated with behavioral severity; direct upstream driver of PDE4 upregulation and adenosine accumulation

ClaimLarge ASD cohort (n=97 ASD, n=87 controls) demonstrating significantly elevated plasma TNF-α, IL-1β, IL-6, and IL-17 in ASD, with cytokine levels negatively correlated with adaptive behavior scores. These are precisely the cytokines that upregulate PDE4 via NF-κB (GP-3) and drive the neuroinflammatory ATP depletion that generates adenosine accumulation (GP-4). Provides direct human population-level evidence for the cytokine burden that constitutes the upstream driver of the somatostatin lock in 04B's framework.

EvidenceHuman / case-control cohort

6 citations

IMMUNOGLOBULIN THERAPY — IVIG & IMIG IN ASD

These citations support Document 14: Biology of Autism — Immunoglobulin Therapy. They cover the systematic evidence base for IVIG in ASD, IgG abnormalities in ASD subgroups, the first published IMIG case report, and the key discontinuation studies establishing that sustained immunomodulation is required for durable benefit.

IG-1

[IG-1] Rossignol DA, Frye RE. A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder. J Pers Med. 2021;11(6):488.

DOI🔗 https://doi.org/10.3390/jpm11060488

NodeUpstream immune modulation — IVIG therapeutic evidence base

ClaimSystematic review of 27 IVIG publications in ASD. Meta-analysis demonstrated large effect sizes for total aberrant behaviour (d′=0.80) and irritability (d′=0.87), and medium effect sizes for hyperactivity and social withdrawal. IgG abnormalities identified in subsets: depressed total IgG correlated with behavioural severity; elevated IgG4 correlated with social impairment.

EvidenceSystematic review & meta-analysis

IG-2

[IG-2] Fourie PR, Armstrong JC. Intramuscular Immunoglobulins as a Therapeutic Modality for Neural Inflammation in patients with ASD and PANS: A Combined Case Report. Medical Research Archives. 2024;12(9).

DOI🔗 https://doi.org/10.18103/mra.v12i9.5984

NodeUpstream immune modulation — first published IMIG case report in ASD and PANS

ClaimFirst published case report of intramuscular immunoglobulin (IMIG) in ASD and PANS. Seven level 2 ASD children treated monthly with NBI Intragam (16% IgG, 0.2 mL/kg): 6/7 scored above zero, mean improvement +2.9/5. Five PANS children: all scored above zero, mean +4.4/5. IMIG proposed as cost-effective alternative to IVIG for neuroinflammation management.

EvidencePublished case report

IG-3

[IG-3] Boris M, Goldblatt A, Edelson SM. Improvement in children with autism treated with intravenous gamma globulin. J Nutr Environ Med. 2005;15(4):169–176.

NodeUpstream immune modulation — IVIG discontinuation / sustained treatment requirement

Claim26 children with ASD and neurodevelopmental regression treated with IVIG 0.4 g/kg monthly for 6 months. Significant improvements in all ABC subscales. 22/26 (85%) lost some improvements when IVIG was stopped — establishing that sustained immunomodulation, not a completed course, is required for durable benefit.

EvidenceRetrospective case series

IG-4

[IG-4] Maltsev DV, Yevtushenko SK. High-Dose Intravenous Immunoglobulin Therapy Efficiency in Children with Autism Spectrum Disorders Associated with Genetic Deficiency of Folate Cycle Enzymes. Int Neurol J. 2016;2:35–48.

NodeUpstream immune modulation — IVIG outcomes and discontinuation

Claim78 ASD children treated with IVIG 2 g/kg monthly for 6 months. Complete elimination of ASD phenotype in 27%, marked improvement in 42%, mild-to-moderate improvement in 29%. Of those with mild-to-moderate improvement, 50% lost gains 2–4 months after completing therapy. Corroborates the discontinuation pattern across multiple studies.

EvidenceRetrospective controlled

IG-5

[IG-5] Melamed IR, Heffron M, Testori A, Lipe K. A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation. Autism Res. 2018;11(3):421–433.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/29316328/

NodeUpstream immune modulation — IVIG + cytokine reduction

Claim14 ASD children with immune abnormalities treated with IVIG 1 g/kg for 10 doses. Significant improvements on CGI, SRS, and ABC hyperactivity subscale. Significant decreases in TNF-α induced by TLR ligands — directly confirming that IVIG suppresses the upstream cytokines driving IDO1 activation in the cascade model.

EvidenceProspective uncontrolled

IG-6

[IG-6] Connery K, Tippett M, Delhey LM, et al. Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Transl Psychiatry. 2018;8(1):148.

PubMed🔗 https://pubmed.ncbi.nlm.nih.gov/30108200/

NodeUpstream immune modulation — IVIG in autoimmune encephalopathy / ASD

Claim31 ASD children with autoimmune encephalopathy (confirmed by brain autoantibodies) treated with IVIG 0.75–2 g/kg every 2–6 weeks, 77% for more than one year. Significant improvements on SRS and ABC total scores. Anti-Dopamine D2L and anti-tubulin antibodies (Cunningham panel) predicted response — establishing a biomarker pathway for patient selection.

EvidenceRetrospective case series